Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 1:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Osteoporosis
Interventions
LY2541546, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 85 Years · Female only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Gainesville, Georgia • Bethesda, Maryland
Conditions
Osteoporosis
Interventions
Placebo, DP001
Drug
Lead sponsor
Deltanoid Pharmaceuticals
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Upland, California • Indianapolis, Indiana • Bethesda, Maryland + 6 more
Conditions
Breast Cancer, Osteoporosis
Interventions
letrozole, zoledronic acid
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Postmenopausal Osteoporosis
Interventions
teriparatide, aldrenodate, raloxifene
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
10
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 7 more
Conditions
Breast Cancer
Interventions
Anastrozole, Risedronate Sodium
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years and older · Female only
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Palm Springs, California • Jacksonville, Florida • New Orleans, Louisiana + 5 more
Conditions
Osteoporosis, Postmenopausal
Interventions
teriparatide, raloxifene HCl, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Maywood, Illinois • Portland, Oregon
Conditions
Osteoporosis, Post-Menopausal
Interventions
Raloxifene, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
2
States / cities
Indianapolis, Indiana • Omaha, Nebraska
Conditions
Osteoporosis, Postmenopausal, Diabetes Mellitus, Type 2
Interventions
GLP-1 receptor agonist
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
55 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Jackson, Mississippi
Conditions
Osteoporosis, Postmenopausal
Interventions
Arzoxifene, Raloxifene
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Gainesville, Georgia • Urbandale, Iowa • Billings, Montana + 2 more
Completed Not applicable Interventional Accepts healthy volunteers

Calorie Restriction With Leucine Supplementation

NCT01757340
Conditions
Obesity, Menopause, Osteoporosis, Sarcopenia
Interventions
Weight loss with normal protein and leucine intake, Weight loss with protein/leucine supplementation
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years to 65 Years · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Osteoporosis
Interventions
Zoledronic acid, Placebo, Teriparatide
Drug
Lead sponsor
Novartis
Industry
Eligibility
45 Years to 89 Years · Female only
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 15 more
Conditions
Postmenopausal Osteoporosis
Interventions
Romozosumab, Teriparatide
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Gainesville, Georgia • Bethesda, Maryland • Boston, Massachusetts + 1 more
Conditions
Osteoporosis
Interventions
teriparatide, Placebo, BA058 20 µg, BA058 40 µg, BA058 80 µg
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Post-Menopausal Osteoporosis
Interventions
romosozumab HCP administration with PFS, romosozumab self-administration with AI/Pen
Drug · Device
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 30 more
Conditions
Postmenopausal Osteoporosis
Interventions
Romosozumab, Placebo, Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
7,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
25
States / cities
Tucson, Arizona • Laguna Hills, California • Los Angeles, California + 22 more
Conditions
Post Menopausal Osteoporosis
Interventions
Denosumab, Zoledronic Acid, Placebo to Denosumab, Placebo to Zoledronic Acid
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years and older · Female only
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
Santa Monica, California • Lakewood, Colorado • Longmont, Colorado + 6 more
Conditions
Osteoporosis
Interventions
PTH/Calcium, PTH/placebo, placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
45 Years and older · Female only
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
17
States / cities
Rancho Cucamonga, California • Lake Worth, Florida • Coeur d'Alene, Idaho + 14 more
Completed No phase listed Observational Results available

Study Evaluating Changes In Mammographic Breast Density

NCT00774267
Conditions
Osteoporosis
Interventions
BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene 60 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more
Conditions
Osteoporosis
Interventions
Raloxifene, Zoledronic acid, Placebo oral pills, Placebo intravenous (i.v.) infusion
Drug
Lead sponsor
Novartis
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Phoenix, Arizona • Buena Park, California • Washington D.C., District of Columbia + 12 more
Completed Phase 3 Interventional

Open Label Extension

NCT00172120
Conditions
Osteoporosis
Interventions
ALX1-11
Drug
Lead sponsor
Shire
Industry
Eligibility
45 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
9
States / cities
Beverly Hills, California • Chicago, Illinois • Detroit, Michigan + 6 more
Conditions
Post-Menopausal Osteoporosis
Interventions
ibandronate [Bonviva/Boniva]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
6
States / cities
Gainesville, Georgia • St Louis, Missouri • Omaha, Nebraska + 3 more
Conditions
Breast Cancer, Osteoporosis
Interventions
zoledronic acid, Letrozole as adjuvant therapy
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Conditions
Osteoporosis
Interventions
ALX1-11 (drug)
Drug
Lead sponsor
Shire
Industry
Eligibility
45 Years and older · Female only
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
84
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 75 more
Conditions
Osteoporosis, Atypical Femoral Fracture
Interventions
teriparatide
Drug
Lead sponsor
Susan L. Greenspan
Other
Eligibility
Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania